INmune Bio, Inc.
CORDStrom
Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Countdown
9days
FDA decision · Jul 15, 2026
What's at stake
The FDA's approval decision on CORDStrom for Recessive Dystrophic Epidermolysis Bullosa (RDEB) is due Jul 15, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 11h ago
“Following the planned MAA submission to the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), we anticipate submitting a Biologics License Application (BLA) to the U.S. FDA toward the end of 2026.”